

*Sub
B3
cont.*
*A1
cont.*

wherein said packaging material comprises a label or a written material which indicates that the compound identified in claim 10 can or should be used for preventing and/or treating dysuria.--

SUPPORT FOR THE AMENDMENT

Claims 10-20 find support in the specification at pages 32-37 that describe the compounds of formulas (IV), (V), (VI), (VII) and (VIII). Prodrugs are described on page 48, lines 1-2 of the specification. Accordingly, the Applicants do not believe that any new matter has been added.

REMARKS


Claims 1-20 are pending.

CONCLUSION

Applicants respectfully submit that the claims are now in condition for early examination on the merits.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No.: 24,618



22850

Thomas M. Cunningham
Registration No.: 45,394

PHONE NO.: (703) 413-3000
FAX NO.: (703) 413-2220

.219501US-0 CONT

Marked-Up Copy
Serial No: 10/074,020
Amendment Filed Herewith

IN THE CLAIMS

Add new claims 10-20.

--10-20. (New)--

